0.8812 -0.077 (-8%) | 11-13 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1.01 | 1-year : | 1.18 |
Resists | First : | 0.87 | Second : | 1.01 |
Pivot price | 0.71 | |||
Supports | First : | 0.7 | Second : | 0.6 |
MAs | MA(5) : | 0.76 | MA(20) : | 0.71 |
MA(100) : | 1 | MA(250) : | 1.19 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 91.5 | D(3) : | 72.2 |
RSI | RSI(14): 55.5 | |||
52-week | High : | 1.99 | Low : | 0.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SELB ] has closed below upper band by 7.1%. Bollinger Bands are 4.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.87 - 0.88 | 0.88 - 0.88 |
Low: | 0.79 - 0.8 | 0.8 - 0.8 |
Close: | 0.83 - 0.84 | 0.84 - 0.85 |
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Thu, 18 Jan 2024
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cartesian Therapeutics, Inc. (NASDAQ: RNAC ... - PR Newswire
Tue, 14 Nov 2023
Further weakness as Selecta Biosciences (NASDAQ:SELB) drops 17% this week, taking five-year losses to 85% - Yahoo Finance
Mon, 13 Nov 2023
Why Selecta Biosciences (SELB) Stock Is Sliding Today - Benzinga
Mon, 13 Nov 2023
Selecta Biosciences Announces Merger with Cartesian Therapeutics - GlobeNewswire
Mon, 13 Nov 2023
Selecta Biosciences and Cartesian Therapeutics Announce Merger to Form Public Company Focused on RNA Cell ... - BioBuzz
Tue, 31 Oct 2023
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization ... - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 153 (M) |
Shares Float | 94 (M) |
Held by Insiders | 25 (%) |
Held by Institutions | 47.7 (%) |
Shares Short | 7,980 (K) |
Shares Short P.Month | 9,460 (K) |
EPS | -0.29 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.43 |
Profit Margin | -72 % |
Operating Margin | -355.1 % |
Return on Assets (ttm) | -18 % |
Return on Equity (ttm) | -45.3 % |
Qtrly Rev. Growth | -86.6 % |
Gross Profit (p.s.) | 0.25 |
Sales Per Share | 0.31 |
EBITDA (p.s.) | -0.31 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -26 (M) |
Levered Free Cash Flow | -12 (M) |
PE Ratio | -2.9 |
PEG Ratio | 0 |
Price to Book value | 1.95 |
Price to Sales | 2.64 |
Price to Cash Flow | -4.93 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |